Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2025)
Novartis Ag (NVS) posted Income from Non-Controlling Interests of -$5.0 million for Q4 2025, down 350.0% sequentially from $2.0 million in Q3 2025, and down 350.0% YoY from $2.0 million in Q4 2024.
Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2025) Analysis & Trends
Novartis Ag (NVS) has 15 years of Income from Non-Controlling Interests data on file, last reported at -$5.0 million in Q4 2025.
- Quarterly Income from Non-Controlling Interests fell 350.0% year-over-year to -$5.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$20.0 million (down 2100.0% YoY) and the FY2025 annual result came in at -$17.0 million, down 750.0% from the prior year.
- Income from Non-Controlling Interests retreated to -$5.0 million in Q4 2025 per NVS's latest filing, from $2.0 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $3.0 million in Q1 2025, with the low at -$17.0 million in Q2 2025.
- Average Income from Non-Controlling Interests over 5 years is -$1.3 million, with a median of $1.0 million recorded in 2022.
- Year-over-year, Income from Non-Controlling Interests soared 200.0% in 2022 and plunged 350.0% in 2025.
- Novartis Ag's Income from Non-Controlling Interests stood at -$2.0 million in 2021, then changed by 0.0% to -$2.0 million in 2022, then soared by 200.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then sank by 350.0% to -$5.0 million in 2025.
- Business Quant data shows NVS's Income from Non-Controlling Interests at -$5.0 million in Q4 2025, $2.0 million in Q3 2025, and -$17.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -17.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | -2.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | -3.00 Mn |
| Dec 31, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.00 Mn |
| Dec 31, 2020 | 5.00 Mn |
| Sep 30, 2020 | -3.00 Mn |
| Mar 31, 2020 | -3.00 Mn |
| Dec 31, 2019 | 4.00 Mn |
| Sep 30, 2019 | -1.00 Mn |